Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Munich, Germany.
Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Munich, Germany; Munich Heart Alliance, Partner Site German Center for Cardiovascular Disease, Munich, Germany.
JACC Cardiovasc Interv. 2021 Jun 14;14(11):1243-1253. doi: 10.1016/j.jcin.2021.03.050. Epub 2021 May 12.
The aim of this study was to assess the impact of residual mitral regurgitation (resMR) on mortality with respect to left ventricular dilatation (LV-Dil) or right ventricular dysfunction (RV-Dys) in patients with secondary mitral regurgitation (SMR) who underwent mitral valve transcatheter edge-to-edge repair (TEER).
The presence of LV-Dil and RV-Dys correlates with advanced stages of heart failure in SMR patients, which may impact the outcome after TEER.
SMR patients in a European multicenter registry were evaluated. Investigated outcomes were 2-year all-cause mortality and improvement in New York Heart Association functional class with respect to MR reduction, LV-Dil (defined as LV end-diastolic volume ≥159 ml), and RV-Dys (defined as tricuspid annular plane systolic excursion-to-systolic pulmonary artery pressure ratio of <0.274 mm/mm Hg).
Among 809 included patients, resMR ≤1+ was achieved in 546 (67%) patients. Overall estimated 2-year mortality rate was 32%. Post-procedural resMR was significantly associated with mortality (p = 0.031). Although the improvement in New York Heart Association functional class persisted regardless of either LV-Dil or RV-Dys, the beneficial treatment effect of resMR ≤1+ on 2-year mortality was observed only in patients without LV-Dil and RV-Dys (hazard ratio: 1.75; 95% confidence interval: 1.03 to 3.00).
Achieving optimal MR reduction by TEER is associated with improved survival in SMR patients, especially if the progress in heart failure is not too advanced. In SMR patients with advanced stages of heart failure, as evidenced by LV-Dil or RV-Dys, the treatment effect of TEER on symptomatic improvement is maintained, but the survival benefit appears to be reduced.
本研究旨在评估二尖瓣经导管缘对缘修复术(TEER)治疗继发性二尖瓣反流(SMR)患者时,残余二尖瓣反流(resMR)对死亡率的影响,以及左心室扩张(LV-Dil)或右心室功能障碍(RV-Dys)对死亡率的影响。
LV-Dil 和 RV-Dys 与 SMR 患者心力衰竭的晚期阶段相关,这可能会影响 TEER 后的结果。
对欧洲多中心注册处的 SMR 患者进行评估。研究结果为 2 年全因死亡率以及与 MR 减少、LV-Dil(定义为 LV 舒张末期容积≥159ml)和 RV-Dys(定义为三尖瓣环平面收缩期位移与收缩期肺动脉压比值<0.274mm/mm Hg)相关的纽约心脏协会功能分级改善。
在 809 例纳入患者中,546 例(67%)患者实现了 resMR≤1+。总体估计 2 年死亡率为 32%。术后 resMR 与死亡率显著相关(p=0.031)。尽管无论 LV-Dil 或 RV-Dys 如何,纽约心脏协会功能分级的改善仍然持续,但仅在没有 LV-Dil 和 RV-Dys 的患者中观察到 resMR≤1+对 2 年死亡率的有益治疗效果(风险比:1.75;95%置信区间:1.03 至 3.00)。
TEER 实现理想的 MR 减少与 SMR 患者的生存率提高相关,特别是在心力衰竭进展不太严重的情况下。在心力衰竭晚期阶段的 SMR 患者中,LV-Dil 或 RV-Dys 证明了这一点,TEER 在改善症状方面的治疗效果得以维持,但生存获益似乎减少了。